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Oxidative stress is a major and recurring cause of damage during inflam-
mation, especially following organ transplantation. Initial ischaemia–rep-
erfusion injury causes the production of many reactive oxygen and
nitrogen species, and subsequent recruitment and activation of inflamma-
tory cells can lead to further oxidative stress. This stress is well known to
cause damage at the cellular level, for example by induction of senescence
leading to the production of a characteristic senescence-associated secre-
tory phenotype. Chemokines are an important component of the senes-
cence-associated secretory phenotype, recruiting further leucocytes and
reinforcing the stress and senescence responses. As well as inducing the
production of proteins, including chemokines, oxidative stress can alter
proteins themselves, both directly and by induction of enzymes capable of
modification. These alterations can lead to important modifications to
their biological activity and also alter detection by some antibodies,
potentially limiting the biological relevance of some immunochemical and
proteomic biomarkers. Peroxynitrite, a reactive nitrogen species generated
during inflammation and ischaemia, can cause such modifications by
nitrating chemokines. Matrix metalloproteinases, released by many
stressed cells, can cleave chemokines, altering function, while peptidylargi-
nine deiminases can inactivate certain chemokines by citrullination. This
review discusses the relationship between inflammation and post-transla-
tional modification, focusing on the functional modulation of transplant-
relevant pro-inflammatory chemokines.
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Introduction
It is well known that inflammation is a complex response
to both infection and tissue injury. It is necessary for the
resolution of damage, but if uncontrolled, chronic inflam-
mation can occur. The sustained recruitment of leuco-
cytes and consequent oxidative stress can lead to
worsening injury; tight regulation of inflammation is
therefore crucial.
The migration of leucocytes to sites of inflammation is
mediated by a specific class of cytokines termed chemo-
kines. These chemokines are produced in response to the
various stresses that occur during inflammation. What is
increasingly clear is that these stresses can have profound
effects on the capacity of chemokines to elicit targeted
immune cell recruitment. The present review will summa-
rize the stresses occurring during inflammation, particu-
larly those which transplanted organs experience, and
what affects these and other stress-related molecules have
on chemokine biology.
Stress
There are many causes of stress and damage to tissues
linked to inflammation, and even more linked to trans-
plantation. During all stages of organ transplantation
there are opportunities for cellular stress and this has
consequences for graft outcome. Oxidative stress is the
Abbreviations: GAG, glycosaminoglycan; MMP, matrix metalloproteinase; NOS, nitric oxide synthase; PAD, peptidylarginine dei-
minase; PPAD, peptidylarginine deiminase from Porphyromonas gingivalis; RNS, reactive nitrogen species; ROS, reactive oxygen
species; SpyCEP, Streptococcus pyogenes cell envelope protease
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major cause of cellular stress and can occur at multiple
points throughout the life of the graft. For example, when
the blood supply returns to tissues after a period of surgi-
cal ischaemia, ischaemia–reperfusion injury can occur.1
This is a major cause of organ dysfunction following sur-
gery. Intracellular oxidative stress under these conditions
is generated by mitochondria and oxidases in epithelial
and endothelial cells.
Pathological oxidative stress arises due to an imbalance
of the producers and scavengers (antioxidants) of reactive
oxygen species and reactive nitrogen species (ROS/RNS),
altering the normal redox state of cells. These reactive
species accumulate in cells or tissues, affecting numerous
cellular pathways and macromolecules. A major source is
electron leakage from the mitochondria during aerobic
respiration.2–4 Peroxisomes, the site of lipid metabolism,
and NADPH oxidase in the plasma membrane of acti-
vated macrophages also produce ROS.5 Vascular adhesion
protein-1, an amine oxidase present at increased levels on
inflamed endothelium, for example in the liver, produces
hydrogen peroxide and is linked to leucocyte recruitment
during inflammation.6 During chronic inflammation
nitric oxide synthase 2 (NOS2) is up-regulated in almost
all liver cells,7 further increasing the potential for perox-
ynitrite formation.
The infiltration of immune cells able to perform oxida-
tive burst, for example macrophages and neutrophils, fur-
ther increases stress by the release of multiple reactive
species. Macrophages produce nitric oxide and superoxide
by inducible NOS and NADPH oxidase, which react to
form peroxynitrite. This aids macrophage antimicrobial
function8 and is triggered by L-arginine depletion occur-
ring in inflammation. This is an innate immune effector
mechanism to aid the killing of pathogens but contributes
to inflammation and stress with excess release of reactive
species.
The effects of oxidative stress are varied, depending on
the reactive species involved as well as the concentration,
cell type and environment. Changes at the cellular and
organ level can lead to inflammation, fibrosis and cancer
but many of these alterations are the result of changes at
a molecular level, for example to DNA and proteins.5
Damage to DNA due to oxidative stress includes both
single-base damage and strand breaks.9,10 These can intro-
duce genetic mutations, cause downstream signalling
effects and activate DNA damage repair mechanisms,
potentially resulting in apoptosis or senescence.10 Peroxi-
dation is the main form of lipid damage, causing cell
death both by peroxidation of membrane lipoproteins,
disrupting membrane integrity, and by generation of reac-
tive aldehydes including 4-hydroxynonenal, which interact
with Fas pathways, including Jun N-terminal kinase, lead-
ing to apoptosis.2 This lipid modification is crucial in the
pathogenesis of multiple diseases including atherosclero-
sis.5
Superoxide (•O2
) is often the first free radical pro-
duced; it is short-lived, damaging only macromolecules in
the immediate vicinity. In contrast, hydrogen peroxide
has a longer half-life and can damage molecules directly
as well as acting as a signalling molecule, activating pro-
tein kinase C, for example.9 The effects of the RNS perox-
ynitrite have been extensively reviewed by Szabo et al.11
This reactive species is involved in multiple aspects of
inflammation and ischaemia–reperfusion injury, both
modifying proteins directly and altering transcription fac-
tors such as nuclear factor-jB, resulting in, for example,
altered cell adhesion molecule expression.12 Oxidative
stress can alter other transcription factors such as hypoxia
inducible factor-1a and p53, further developing the stress
response, and can also increase mitochondrial permeabil-
ity allowing signalling molecules to transition to the
nucleus and vice versa.13
All of these mechanisms enable stress to greatly alter
protein production, leading to induction of apoptosis,
necrosis and senescence, and in these altered cellular states
there is further amplification of stress and inflammation.
For example, senescent cells cause the production of the
senescence-associated secretory phenotype including mul-
tiple chemokines, proteases and other pro-inflammatory
factors,14,15 creating a vicious circle of worsening damage,
potentially spreading senescence. Cellular senescence is
known to play a key role in liver allograft rejection.16
Increased expression of chemokine is particularly impor-
tant in such senescent and inflammatory environment sit-
uations because chemokines can recruit inflammatory
cells, further adding to the damaging feedback loop.
This review, however, will focus on the modifications
that happen to chemokines during such stress, in terms
of both post-translational residue modification and pro-
tein expression.
Chemokines
Chemokines, chemoattractant cytokines, are small (8000–
14 000 molecular weight) proteins secreted by many cell
types primarily to direct leucocyte navigation and so have
an important role in stressful and inflammatory condi-
tions such as transplantation.17 Chemokines are a large
protein family consisting of at least 45 ligands and 20
receptors. These ligands are classified both functionally
and structurally. Inflammatory chemokines direct cells to
the site of injury and are expressed in response to stress
and infection, homeostatic chemokines are involved in
development and tissue maintenance and their expression
is more constitutive. Structural classification is based on
the position of the N-terminal cysteines, creating the four
classes: CC, CXC, CX3C and C, with receptor classes
named appropriately.18,19
Chemokine regulation is highly complex and, because
of their role in leucocyte recruitment, this tight regulation
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is crucial. This ensures, for example, that inflammation
does not become uncontrolled and pathogenic. The regu-
lation occurs at multiple levels as shown in Fig. 1. Briefly,
chemokines can be regulated at the transcriptional and
translational level, with inflammatory chemokines espe-
cially being up-regulated in response to stress. Some pre-
formed chemokines are stored in endothelial cells, in
secretory granules including Weibel–Palade bodies, and
released for rapid response to insult.20 Once produced,
the functions of chemokines are also closely regulated by
post-translational modification, receptor expression and
glycosaminoglycan (GAG) binding. All of these can be
modified during stress. Chemokines typically bind and
signal through G-protein-coupled receptors but decoy, or
atypical, receptors can also bind chemokines, generally
with anti-inflammatory effects.21 To form the chemokine
gradients needed for in vivo function,22 chemokines bind
to GAGs such as heparan sulphate. This chemokine
immobilization increases the concentration at the site of
production, aiding the infiltration of cells. Endothelial
expression of these sugars increases during stresses pro-
duced by transplantation, altering the potential to bind
chemokines and so alter the chemokine function.23
Events throughout transplantation effect the produc-
tion of chemokines and therefore inflammation and
graft outcome as reviewed by El-Sawy et al.17 Tissue
stress as early as brain death of the donor can lead to
endothelial dysfunction and chemokine release, and
ischaemia–reperfusion injury also causes the production
of pro-inflammatory factors. Upon reperfusion, pro-
inflammatory cytokines are produced, including tumour
necrosis factor-a and interleukin-1b. These stimulate the
release of preformed chemokines from vascular endothe-
lium, including CCL2 and CXCL8, recruiting macro-
phages and neutrophils, respectively, to the graft.17 The
interferon-c-inducible chemokines CXCL9, CXCL10 and
CXCL11 are rapidly increased following reperfusion, and
are abundant in rejecting allografts. However, contro-
versy surrounds the role of their receptor, CXCR3, in
transplantation.24
Epithelial cells including those of the liver and kidney
also have potent chemokine-producing ability. Such com-
partments are therefore particularly capable of eliciting an
increase in lymphocyte recruitment, causing the bile-duct
and peritubular inflammation seen in rejection.17 Later
stages of transplant rejection, including arteriosclerosis
and fibrosis, are increased by chemokines25,26 and a grow-
ing body of research shows that chemokine levels could
be used as biomarkers, such as CXCL10 for monitoring
graft inflammation and predicting liver fibrosis.27
Chemokines are involved in senescence, with particular
focus on components of senescence-associated secretory
phenotype including the CXCR2 ligands,14 CXCL1 and


















CitCit Figure 1. Mechanisms of chemokine regula-
tion. Chemokine function is regulated at many
levels. Protein production is regulated at both
the transcriptional and translational level, with
some microRNAs regulating mRNA levels.
Chemokine post-translational modification
occurs both intra- and extra-cellularly for
example nitration, citrullination and protein
cleavage, all of which can alter chemokine
function. Chemokines bind and signal through
‘typical’ G-protein-coupled receptors, this trig-
gers downstream signalling and causes cell
migration. Atypical receptors, including duffy
antigen/chemokine receptor (DARC), however,
bind chemokine, reducing bioavaliability, but
do not signal in the normal manner. Chemo-
kines need to bind glycosaminoglycans
(GAGs), for example heparan sulphate, for in
vivo function. GAGs are presented on the
endothelium and bind chemokine, forming a
chemokine gradient, enabling cell migration.
N, chemokine nitration; Cit, chemokine citrul-
lination.
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molecules, further increases inflammation, senescence
and, in the case of transplantation, potentially organ loss.
Post-translational modification of chemokines
The function of chemokines, as with many proteins, can
be profoundly altered by post-translational modification,
as reviewed in detail by Mortier et al.28 These modifica-
tions can abrogate or enhance, and in a few cases are
mandatory for, chemokine function and so act as a pow-
erful regulatory mechanism to fine tune chemokine func-
tion. Modification can be both enzymatic and chemical,
altering peptide length or modifying amino acids directly.
These modifications can profoundly alter chemokine
behaviour, changing which receptors they target, their
presentation by GAGs and our ability to detect them with
current antibodies. Multiple factors involved in tissue
stress influence these modifications.
Cleavage
Multiple enzyme families can cleave chemokines, particu-
larly at the disordered N-terminus, although some exam-
ples of C-terminal cleavage have been found.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs), zinc-dependent endo-
peptidases, are involved in extracellular matrix degrada-
tion and remodelling and multiple members of the family
are up-regulated following transplantation and during
inflammation. MMP-2 and MMP-9, for example, are
up-regulated during ischaemia–reperfusion.29,30 Other
MMPs are strongly associated with immune cells includ-
ing the neutrophil-associated MMP-8 and the macro-
phage-specific MMP-12.31 Reactive nitrogen species can
also up-regulate MMPs.32 As well as involvement in tissue
remodelling these enzymes also have important roles in
modifying bioactive molecules such as chemokines.
MMP-8 is released from many inflammatory cells
including infiltrating neutrophils. N-terminal cleavage of
CXCL5 and CXCL8 by this enzyme increases chemotactic
activity.33 CXCL8 further increases MMP release from
neutrophils, and matrix component degradation by the
enzyme further facilitates cell migration into the tissue,
creating a feedback loop, amplifying cell recruitment and
potentially leading to worsening damage if unresolved.
MMP-1 and MMP-9 also cleave CXCL8.34,35
Chemokine inactivation also occurs by MMP cleavage.
MMP-12 cleaves and inactivates ELR (glutamic acid-
leucine-arginine) containing CXC chemokines, including
CXCL8,31 at the important motif E-LR. Later in inflamma-
tion, cleavage of CCL2, -7, -8 and -13 results in loss of
activity and the formation of potent antagonists31 that may
actively suppress macrophage recruitment, promoting
resolution and preventing damage. There is specificity
between ligand and substrate, indicating tight control of
chemokine regulation. An example of this is CCL2 and
CCL7, which are co-expressed and share the receptor
CCR2. CCL2 can be cleaved by MMP-1 and MMP-3 but
not by MMP-2. MMP-2, however, can cleave and inacti-
vate other chemokines including CCL7.36
CD26
Several other enzymes can also process chemokines. For
example, the serine protease CD26 (dipeptidyl peptidase-
4; DPP4). CD26 is a membrane glycoprotein expressed by
numerous cell types. It is highly expressed on T cells and
is associated with several aspects of immune regulation
including T-cell proliferation, and inhibition of this
enzyme has been investigated as a therapy for transplant
rejection.37 CXCL11 cleavage by CD26 prevents chemo-
taxis but the chemokine is still able to desensitize the
receptor CXCR3 and so can decrease the local activity of
full-length CXCL11.38 CCL5 is also subject to post-trans-
lational processing by CD26, which cleaves the first two
N-terminal amino acids, preventing binding to CCR139
and CCR3,40 but CCR5 signalling is still intact, skewing
the chemokine towards T-cell recruitment. Interestingly,
CD26 cleavage increases the anti-viral properties of CCL5
against HIV.39 CCL4 also has altered receptor usage fol-
lowing CD26 cleavage, it still binds CCR5 but unlike the
full form also binds CCR1 and CCR2,41 altering the cell
types that it can recruit. To further complicate chemokine
processing in vivo, GAG binding protects CXCL12 from
proteolysis by CD26.42 Cleavage by other enzymes is also
impaired by GAG binding, including the plasmin cleavage
of CCL11.43
Infection
As well as enabling fine tuning of the chemokine system
during inflammation, chemokine cleavage has been used
by bacteria to evade the immune response. The pathogen
Streptococcus pyogenes can express SpyCEP (S. pyogenes
cell envelope protease), which cleaves chemokines con-
taining an ELR motif, including CXCL8.44 This cleavage
inactivates the chemokine, unusually at the C-terminus,
with functional effects most likely due to disruption of
GAG binding and dimerization rather than receptor bind-
ing. SpyCEP is a potent virulence factor, helping the bac-
teria to evade the immune response by decreasing
neutrophil recruitment, and is crucial to aggressive bacte-
rial dissemination,45 increasing, for example, lethal necro-
tizing fasciitis.44
Porphyromonas gingivalis, a bacterium implicated in
periodontal disease, also produces enzymes capable of
chemokine cleavage called gingipains.46,47 These enzymes
can both cleave CXCL8 into more potent forms of the
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chemokine and degrade it, abrogating function, depend-
ing on whether the enzyme is soluble or membrane
bound.
Although functional alterations produced by the modi-
fications discussed so far have been researched, the effects
on epitope loss and therefore detection by many common
methods have not been characterized. This is a funda-
mental problem as discussed later.
Residue modification
Modification of chemokines by direct alteration of amino
acid residues will now be discussed. This can be either
non-enzymatic or enzyme-catalysed.
Nitration
As discussed previously, transplantation and associated
inflammation involve oxidative stress. The RNS peroxyni-
trite is formed by the rapid reaction of nitric oxide and
superoxide and is present in many inflammatory situa-
tions.11 Like other components of oxidative stress, perox-
ynitrite has both molecular and cellular effects, inducing
apoptosis and senescence. Peroxynitrite can selectively
oxidize and nitrate several residues, including the oxida-
tion of histidine and the nitration of tyrosine and trypto-
phan. As shown in Fig. 2(a), nitration of tyrosine results
in the formation of 3-nitrotyrosine. This gives the modi-
fied residue a 45-Da mass increase but the overall charge
remains unaltered. 3-Nitrotyrosine is a marker of nitro-
oxidative stress and the presence of peroxynitrite and is
seen in many pathological conditions including diabe-
tes.11 Antibodies have been raised against 3-nitrotyrosine
and are used to identify nitrated proteins and the pres-
ence of peroxynitrite or related species.11 Figure 3 dem-
onstrates the use of such antibodies to show the presence
of peroxynitrite in a murine model of kidney ischaemia–
reperfusion injury (unpublished data from our group).
Nitration is not a silent modification and can have pro-
found effects on protein function. Effects include attenua-
tion of antioxidants, creating a positive feedback loop
further increasing oxidative stress. Peroxynitrite inactiva-
tion of copper/zinc superoxide dismutase is by modifica-
tion of a histidine48 residue in the active site. Manganese
superoxide dismutase inactivation, however, is by nitra-
tion of a specific tyrosine residue in the active site, which
prevents catalysis. This has been observed in human renal
allografts undergoing chronic rejection,49 contributing to
the positive feedback loop and worsening inflammation.
As discussed earlier, chemokines are present at
increased levels during periods of oxidative stress and so
could be targets of modification. Several chemokines have
been found to be targets of peroxynitrite modification
including CCL250,51 and CCL5.52 Generally it is thought
that modification of pro-inflammatory cytokines by































Figure 2. Post-translational modifications to
the amino acids tyrosine and arginine. (a)
Nitration of tyrosine by peroxynitrite results in
the formation of 3-nitrotyrosine. This reaction
can occur to both peptidyl and free tyrosine
residues. (b) Citrullination is the deimination
of arginine to citrulline by peptidylarginine
deiminase. The substrate for this enzyme is
peptidylarginine, the reaction does not occur
on free arginine. Production of free citrulline,
however, can occur as a by-product of nitric
oxide synthase (NOS) or the urea cycle. Both
of these modifications are not just passive, they
can alter protein function, for example chemo-
kines.
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numerous factors, including cell type. One study shows
that peroxynitrite-treated CCL2 loses its ability to recruit
CD8+ T cells but the recruitment of myeloid-derived sup-
pressor cells is unaltered.50 An earlier study, however,
shows that CCL2 nitration impairs monocyte recruit-
ment.51 No mechanisms of action have been defined in
these papers, but as yet unpublished data from our group
suggest that nitration of CCL2 decreases its chemotactic
ability by both decreasing binding to the receptor CCR2,
and by abrogating its GAG binding ability.
Although not able to nitrate chemokines, the ROS
hydrogen peroxide can modify chemokines by causing
oxidative cross-linking of tyrosine residues in CCL5.53
This causes multimer formation of the chemokine but
does not alter T-cell chemotaxis or receptor usage. Inter-
estingly, GAG binding prevents this modification from
occurring.
The ability of factors involved in oxidative stress to
both induce the production of chemokines and to down-
regulate their function, promoting the resolution of
inflammation, further adds to the complexity of chemoki-
ne regulation.
Molon et al.50 reported that nitrated CCL2 cannot be
detected by commercially available antibodies because the
modification causes epitope loss. This has important
implications for studies using antibody-based techniques
to study chemokine levels in a stressful and inflammatory
environment, as discussed later.
Citrullination
Enzymatic residue modification of chemokines includes
citrullination. This is the formation of citrulline by the
deimination of arginine, by peptidylarginine deiminase
(PAD). This modification only occurs post-translationally
as the enzyme substrate is peptidylarginine not free argi-
nine.
As shown in Fig. 2(b), citrullination gives a 1-Da mass
reduction per arginine residue modified but more pro-
found functional consequences are likely to result from
loss of the basic charge. This is especially likely for
chemokines that strongly rely on their cationic residues
for GAG interactions. Arginine residues often play an
important role in the structural integrity of proteins
because of ionic interactions with negatively charged resi-
dues and cofactors, and by forming hydrogen bonds. Cit-
rullination could logically therefore lead to changes in
protein structure and hence function.
Five human PAD isoforms have been identified and
their roles in pathology and chemokine interactions have
been reviewed by Moelants et al.54 The isoforms have dif-
fering tissue expression patterns, and substrate specificity
is also exhibited, For example only PAD2 citrullinates
b-actin, and only PAD4 citrullinates histone H3.55 PADs
are expressed by the epidermis, granulocytes, lymphocytes
and some epithelial cells, with increased expression asso-
ciated with a range of inflammatory diseases including
rheumatoid arthritis and multiple sclerosis. Stress-acti-
vated pathways involving p53 both regulate and are regu-
lated by PAD4 citrullination,56 with autocitrullination
further regulating enzyme activity.57
All human PAD isoforms are calcium binding and cal-
cium levels are crucial in regulating enzyme activity.54
Normal intracellular calcium levels are insufficient for
function, but oxidative stress is known to cause an influx
of cytoplasmic calcium, suggesting that PAD will be active
in situations such as ischaemia–reperfusion and inflam-
mation. Serum PAD has increased activity in rheumatoid
arthritis patients.58
Citrullination of multiple protein families has been
identified, including the structural proteins actin and cy-
tokeratin. Histone citrullination alters chromatin remod-
elling and so affects protein expression. Citrullination is
also needed for neutrophil extracellular trap formation
and so is heavily involved in immune regulation.54
Chemokines can be citrullinated and, as with nitration,
this is not a silent modification, but can affect function.
All modifications found so far show citrullination to be
an anti-inflammatory modification, decreasing in vivo
chemokine function. Citrullination of both CXCL10 and
CXCL11 does not alter CXCR3 binding but does result in
a decrease in calcium signalling, chemotactic activity and
heparin binding.59 Studies of CXCL12 show that PAD
decreases function, with an increase in functional impair-
ment correlated with an increased number of citrullinated
arginines.60 Such modified chemokines may occur in, for
example, Crohn’s disease, where co-expression of CXCL12
and PAD has been found.60 CXCL8 has increased CXCR1
Figure 3. Protein nitration in ischaemia–reper-
fusion injury. Kidney sections from a murine
model of ischaemia–reperfusion injury were
stained for 3-nitrotyrosine (brown) and count-
erstained with haematoxylin (blue) by immu-
nohistochemistry. The right kidney was
ischaemic for 45 min and organs were har-
vested 24 hr after reperfusion, the left kidney
is the contralateral control. Magnification 920.
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binding once citrullinated on specific arginines but
decreased heparin binding does not induce neutrophil
chemotaxis in vivo.61 These modifications highlight
important differences between in vivo and in vitro chemo-
kine function.
Bacterial PAD have also been identified, produced by
P. gingivalis although unlike the human isoforms these
can modify both free and peptidyl-arginine and are not
calcium dependent. As yet, chemokine modification by
these enzymes is unconfirmed.47
As well as modifying GAG binding, citrullination may
also have a role in preventing enzymatic cleavage. Citrul-
lination of CXCL8 prevents cleavage by gingipains to
more active forms of the chemokine, so potentially
dampening inflammation.47
Implication for biomarkers and detection
There are an increasing number of studies of stress-
induced proteomic changes following organ transplanta-
tion. Chemokines, due to their role in inflammation, are
logical candidates and are often studied.62 However, mea-
surement of chemokine levels alone, as candidate biomar-
kers of rejection, is not providing the whole picture.27,63
As discussed in this review, it is becoming clear that mea-
surement of the function of post-translationally modified
proteins may be more important than absolute protein
levels; this is particularly relevant for proteins in stressful
situations due to the increased potential for modification.
Post-translational modifications alter the function of
chemokines, both enhancing and abrogating their potency
on a case-by-case basis. Furthermore, in some instances,
such as CCL2, nitration can prevent detection by anti-
bodies, potentially limiting the biological relevance of
some immunochemical and proteomic biomarkers. Not
all modifications affect function and not all alter our abil-
ity to detect protein presence, but it is this heterogeneity
that makes understanding chemokines in the inflamma-
tory environment so important. In the future, more
emphasis should perhaps be placed on measurements of
chemokine function, rather than mere presence. Further-
more, new strategies to measure levels of modified
chemokines, using antibodies specific to modified forms
of chemokine, or mass spectrometry, should be further
developed for more widespread use.
Conclusions
Current knowledge of the post-translational modifica-
tion of chemokines is, on the whole, anecdotal. To fur-
ther our understanding a systematic approach needs to
be adopted to determine which chemokines can be
modified and by what mechanisms. Binding to conven-
tional receptors, immunoregulatory atypical receptors
and GAGs must be assessed on a case-by-case basis to
ascertain true biological potency. Determining both the
functional and antigenic effects of these modifications
is crucial to establish chemokine levels in vivo and the
function of these proteins. It is in stressful and inflam-
matory situations that this is most crucial due to both
increased chemokine levels and increased opportunities
for modification.
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